Last updated: July 17, 2026
Neurocrine Biosciences v. Teva (1:22-cv-00092): Litigation Summary, Claims at Issue, and Expiry Risk for Neurocrine’s Products
Neurocrine Biosciences, Inc. v. Teva Pharmaceuticals, Inc., No. 1:22-cv-00092, filed in the District of Delaware in 2022, is a federal Hatch-Waxman patent infringement case tied to Teva’s challenge and/or launch intent under an FDA drug application. This matter’s actionable risk depends on (1) the specific asserted patents, (2) the Orange Book listing(s) and FDA approval(s) those patents correspond to, and (3) the procedural posture through the current status in PACER and related court filings.
No complete, reliable docket-level details (asserted patent numbers, claim construction, settlement terms, or dispositive outcomes) are provided in the prompt; without those specifics, a complete and accurate litigation analysis cannot be produced under the operating constraints.
What patents are asserted in Neurocrine Biosciences v. Teva 1:22-cv-00092?
Featured snippet answer: The asserted patents are not identified in the provided information, so the patent estate and infringement scope cannot be mapped.
Which patents are typically implicated in this category of Neurocrine v. Teva disputes?
Federal Hatch-Waxman cases involving Neurocrine products commonly target one or more of the following patent categories, depending on the FDA reference product and formulation:
- Composition or formulation patents covering active ingredient and/or release characteristics
- Method-of-use patents tied to patient subpopulations and therapeutic regimens
- Manufacturing or process patents for controlled-release or oral delivery systems
How to interpret “asserted patents” in Hatch-Waxman suits?
For business decisions, the “asserted patents” determine:
- Whether Teva’s ANDA is “carved out” for certain strengths/forms
- Whether an injunction is practically meaningful (each patent’s remaining life and enforceability)
- Whether design-arounds are plausible (formulation/process vs. method-of-use vs. polymorph)
What stage is the case at, and what does that imply for launch timing?
Featured snippet answer: The case stage is not provided, so launch timing and exclusivity pressure cannot be stated.
Key procedural milestones that change risk
- Complaint filing and service timing (marks the formal IP dispute window)
- Claim construction (Narrows infringement theories)
- Summary judgment orders (can end the case or narrow asserted claims)
- Trial verdict or dismissal (terminates infringement exposure)
- Settlement and consent judgment (controls entry and launch triggers)
Settlement signals that matter to generic entry
When Hatch-Waxman cases settle, risk usually shifts to:
- Date-based entry (carve-out launch calendar)
- Patent-based “trigger” (entry allowed only after specific patents expire)
- Dismissal without prejudice vs with prejudice (affects future disputes)
- Stipulated injunction scope (what product/strength is blocked)
What FDA Orange Book listings and NDA/ANDA references are implicated?
Featured snippet answer: The referenced FDA product (NDA/ANDA) and Orange Book listings are not identified in the prompt.
Why Orange Book mapping is necessary for analysis
A litigation summary becomes actionable only when it ties:
- Asserted patents to specific Orange Book entries
- The corresponding dosage form and strength
- The approval pathway (505(b)(1), 505(b)(2), or 505(j) ANDA)
- Whether Teva is attempting to enter before patent expiration via Paragraph IV
“Paragraph IV” and entry risk
If Teva’s filing includes a Paragraph IV certification:
- The case is a “30-month stay” venue unless a triggering exception applies
- The settlement often converts to an “agreed entry” date with a tailored carve-out
How strong is Neurocrine’s patent estate against Teva’s proposed product?
Featured snippet answer: Patent strength cannot be assessed without asserted-patent identity, claim status, and the court’s rulings.
What determines strength in district court for Hatch-Waxman suits
- Surviving independent claims after pleadings and early motions
- Claim construction positions (scope of terms like “extended release,” “particle size,” or “therapeutically effective amount”)
- Validity history (prior art, obviousness, written description, enablement)
- Infringement proof posture (comparative formulations, lab testing, process steps)
- Design-around feasibility (alternative excipients, release mechanisms, or dosing schedules)
What generic entry risks exist for Teva under 1:22-cv-00092?
Featured snippet answer: Entry risk is not quantifiable without the asserted patents, the certified basis, and the case’s current status.
Entry-risk drivers
- Remaining enforceable life of asserted patents
- Whether the case narrowed to fewer patents or claims
- Whether an injunction was entered or stayed
- Whether Teva has a resolved settlement and authorized launch date
How does the litigation affect Neurocrine revenue exposure?
Featured snippet answer: Revenue exposure impact cannot be calculated without the tied product, expected Teva launch timing, and the patent/claim scope.
Revenue impact mechanics
For neuropsychiatric and endocrine assets:
- Price erosion typically begins at first generic authorized sale, not necessarily after litigation concludes
- Formulation-specific exclusivity can preserve market share if generics are blocked for certain strengths/dosage forms
- Settlement terms can cap the portion of the market Teva may enter at launch
Key Takeaways
- The prompt identifies the case caption and docket number only. It does not include asserted patent numbers, FDA product mapping, or procedural outcomes.
- A complete litigation summary and analysis requires the asserted patent estate, Orange Book/NDA context, and docket status.
- Under the provided constraints, actionable, accurate litigation analysis cannot be produced.
FAQs
- What is the purpose of a Hatch-Waxman lawsuit like Neurocrine Biosciences v. Teva?
- How does a Paragraph IV certification link to litigation under docket 1:22-cv-00092?
- What court orders typically determine whether a generic can launch during an appeal?
- How do settlement agreements in patent cases translate into agreed launch dates?
- Which factors most often decide claim construction in formulation and method-of-use disputes?
References
- U.S. District Court, District of Delaware. Case No. 1:22-cv-00092 (Neurocrine Biosciences, Inc. v. Teva Pharmaceuticals, Inc.).
